title: Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.
abstract: It is important to examine variation in the treatment effects of patients with esophageal cancer in order to generalize treatment outcomes. We aimed to investigate the range of prognostic differences among hospitals in the treatment of locally advanced esophageal cancer. The JCOG0303 study compared the efficacy of radiotherapy plus low-dose cisplatin and 5-fluorouracil with that of high-dose cisplatin and 5-fluorouracil for unresectable esophageal cancer. Of 32 institutions participating in the JCOG0303 study, the 18 institutions that enrolled three or more patients were included in this study. We predicted the 1-year survival in each institution by using a mixed-effect model. We found that the predicted 1-year survival in the 18 institutions with three or more patients was a median of 60.9%, with a range of 60.9-60.9%. This study is the first to investigated heterogeneity of survival in patients who received definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
authors.affiliation: Cancer Center, Keio University School of Medicine, Tokyo yhamamoto@z2.keio.jp.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hamamoto
authors.affiliation: Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, Tokyo.
authors.forename: Junki
authors.initials: J
authors.lastname: Mizusawa
authors.affiliation: Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, Tokyo.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Katayama
authors.affiliation: Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, Tokyo.
authors.forename: Kenichi
authors.initials: K
authors.lastname: Nakamura
authors.affiliation: Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo.
authors.forename: Ken
authors.initials: K
authors.lastname: Kato
authors.affiliation: Esophageal Surgical Division, Shizuoka Cancer Center, Shunto-gun.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tsubosa
authors.affiliation: Department of Radiology, Koshigaya Municipal Hospital, Koshigaya.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ishikura
authors.affiliation: Esophageal Surgical Division, National Cancer Center Hospital, Tokyo.
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Igaki
authors.affiliation: Department of Thoracic Surgery, Aichi Cancer Center, Nagoya.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Shinoda
authors.affiliation: Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, Tokyo.
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Fukuda
authors.affiliation: Department of Surgery, Keio University School of Medicine, Tokyo.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kitagawa
authors.affiliation: International Goodwill Hospital, Yokohama, Japan.
authors.forename: Nobutoshi
authors.initials: N
authors.lastname: Ando
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage; D015986:Confounding Factors, Epidemiologic; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin; D005472:Fluorouracil
keywords: chemoradiotherapy; esophageal cancer; heterogeneity
references.citation: Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):354-61
references.pmid: 18931839
references.citation: N Engl J Med. 2014 Dec 25;371(26):2499-509
references.pmid: 25539106
references.citation: J Clin Oncol. 2007 Aug 1;25(22):3224-9
references.pmid: 17664470
references.citation: Int J Clin Oncol. 2012 Apr;17(2):105-11
references.pmid: 21667354
references.citation: Cancer. 2012 Apr 1;118(7):1754-63
references.pmid: 22009562
references.citation: Cancer Sci. 2015 Apr;106(4):407-12
references.pmid: 25640628
references.citation: Br J Surg. 2015 Aug;102(9):1088-96
references.pmid: 26095389
references.citation: J Clin Oncol. 1999 Sep;17(9):2915-21
references.pmid: 10561371
references.citation: World J Surg. 2001 Mar;25(3):279-84
references.pmid: 11343176
references.citation: Dis Esophagus. 2001;14(3-4):197-201
references.pmid: 11869319
references.citation: Radiol Med. 2002 Apr;103(4):344-52
references.pmid: 12107384
references.citation: Radiology. 1983 Feb;146(2):433-8
references.pmid: 6849089
references.citation: Jpn J Clin Oncol. 2004 Oct;34(10):615-9
references.pmid: 15591460
references.citation: World J Surg. 2005 Jan;29(1):25-30; discussion 30-1
references.pmid: 15599735
references.citation: Jpn J Clin Oncol. 2008 Nov;38(11):723-9
references.pmid: 18952706